|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01XE04
|
|
gptkbp:brand
|
gptkb:Sutent
|
|
gptkbp:CASNumber
|
gptkb:557795-19-4
|
|
gptkbp:cause
|
bleeding
proteinuria
QT prolongation
cardiotoxicity
thyroid dysfunction
|
|
gptkbp:chemicalFormula
|
C22H27FN4O2
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Sugen
|
|
gptkbp:eliminationHalfLife
|
40-60 hours
|
|
gptkbp:firstSynthesized
|
1999
|
|
gptkbp:hasBoxedWarning
|
hepatotoxicity
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sunitinib
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits multiple receptor tyrosine kinases
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
398.48 g/mol
|
|
gptkbp:patentExpired
|
2021 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
5329102
CHEMBL535
DB01268
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
diarrhea
fatigue
hypertension
mucositis
|
|
gptkbp:target
|
gptkb:PDGFR
gptkb:VEGFR
gptkb:KIT
gptkb:FLT3
gptkb:RET
gptkb:CSF1R
|
|
gptkbp:UNII
|
UH2A2J35Y7
|
|
gptkbp:usedFor
|
gptkb:gastrointestinal_stromal_tumor
gptkb:pancreatic_neuroendocrine_tumors
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:VEGFR-3
gptkb:DB01234
|
|
gptkbp:bfsLayer
|
7
|